Review of the Literature: Interval SNs in Melanoma Patients
| Study | Patients | Interval SNs | Trunk (%) | Upper limb (%) | Lower limb (%) | Overall metastatic (%) | Metastatic interval SNs |
|---|---|---|---|---|---|---|---|
| McMasters (13) | 2,000 | 62 (3.1%) | 2.7 | 3.8 | 2.0 | 19.5 | 13/64 (20.3%) |
| Uren (14) | 2,045 | 148 (7.2%) | 11.8 | 4.7 | 0.9 | 3/21 (14.3%) | |
| Roozendaal (15) | 379 | 23 (6.1%) | 8.3 | 12.1 | 2.0 | 4/18 (22.2%) | |
| Summer (16) | 1,117 | 59 (5.3%) | 6.9 | 3.9 | 2.3 | 16.9 | 7/54 (13.0%) |
| Vidal-Sicart (17) | 599 | 59 (9.8%) | 15.1 | 12.1 | 4.7 | 17.9 | 10/59 (16.9%) |
| Chakera (11) | 241 | 22 (9.1%) | 22.0 | 0/8 (0%) | |||
| Doting (18) | 200 | 17 (8.5%) | 24.2 | 2/17 (11.8%) | |||
| Thelmo (19) | 557 | 30 (5.4%) | 5/30 (16.7%) | ||||
| Chakera (11) | 402 | 18 (4.6%) | 5.9 | 7.5 | 1.4 | 24.1 | 0/8 (0%) |